Strides Pharma announces NCLT approval for demerger of Arco Lab's business
Strides Pharma Science · Pharmaceuticals & Biotechnology
Key highlights
- NCLT Bengaluru Bench approved Scheme of Arrangement for demerger on May 18, 2026
- Demerged Undertaking of Arco Lab to vest with Pivot Path effective April 10, 2025
- Upon scheme effectiveness, Pivot Path becomes wholly owned subsidiary of Strides Pharma Science Limited
Why it's rated notable: The filing states no value for the demerged Life Sciences and Digital Innovation undertaking, which moves within the wholly owned group of Arco Lab and Strides, so the level stays at medium and the scheme becomes effective only after filing with the Registrar of Companies.
Original filing
Pronouncement Of Order By The Hon'Ble NCLT, Bengaluru Bench Regarding Scheme Of Arrangement For Demerger Of Demerged Undertaking Of Arco Lab Private Limited, A Wholly Owned Subsidiary Of Strides Pharma Science Limited.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Strides Pharma Science
- Dividend / buyback / bonusMajor developmentStrides Pharma Science Limited June quarter results; Pivot Path stake cut to 19.95%
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.